Catalog No.
Product Name
Application
Product Information
Citations
-
Antiepileptic Agent
Otophylloside B is a C-21 steroidal glycoside with significant antiepileptic properties. It is isolated from Qingyangshen and demonstrates protective effects against Aβ toxicity, primarily by reducing Aβ deposition through decreased expression of its mRNA. This compound is valuable for research into neuroprotective strategies and the management of epilepsy. -
Amyloid-β
BTA-1 is an uncharged derivative of thioflavin-T designed to target amyloid-β (Aβ) fibrils. It exhibits a high affinity for Aβ aggregates, facilitating effective binding and visualization in amyloid research. BTA-1 demonstrates excellent brain penetration and clearance, making it a valuable reagent for studies related to neurodegenerative diseases, such as Alzheimer's disease. -
Amyloid-beta precursor protein (APP) synthesis reducer
Mivelsiran is a small interfering RNA (siRNA) that specifically reduces the synthesis of amyloid-beta precursor protein (APP). This compound is primarily utilized in research focusing on Alzheimer's disease, providing insights into the mechanisms of amyloid plaque formation and the associated neurodegenerative processes. Mivelsiran serves as a valuable tool for exploring therapeutic strategies aimed at mitigating APP-related pathologies. -
Amyloid-β Inhibitor
2-Hydroxy-5-(phenyldiazenyl)benzoic acid-d5 is a deuterated derivative of 2-Hydroxy-5-(phenyldiazenyl)benzoic acid that primarily targets amyloid-β. This compound exhibits significant inhibitory activity against amyloid-β aggregation, making it valuable for research related to Alzheimer's disease and other neurodegenerative disorders. It serves as a useful tool for investigating the mechanisms of amyloid pathology and potential therapeutic strategies. -
Antioxidant Agent
Antioxidant Agent-2 is a potent antioxidant and selective metal ion chelator that effectively penetrates the blood-brain barrier. This compound exhibits significant neuroprotective and hepatoprotective effects, making it a valuable tool in the research of Alzheimer's disease and related neurodegenerative disorders. Its ability to mitigate oxidative stress and metal-induced toxicity highlights its potential for therapeutic applications in neurological health. -
LC Kinetic Stabilizer
LC Kinetic Stabilizer-2 is a potent agent designed to stabilize amyloidogenic immunoglobulin light chains (LC) by enhancing their kinetic stability, with an EC50 of 24 nM. This compound is particularly useful in research applications focused on protein misfolding diseases, amyloidosis, and related pathologies. It enables the investigation of LC dynamics and potential therapeutic interventions to prevent aggregation in affected tissues. -
Aβ1-40 Aggregation Activator
Glycerophosphorylethanolamine sodium is an active phosphodiester metabolite of phosphatidylethanolamine that functions as an Aβ1-40 aggregation activator. This compound promotes the aggregation of amyloid β-protein (Aβ1-40) in vitro, facilitating studies related to amyloid plaque formation. Glycerophosphorylethanolamine sodium is particularly relevant for research in neurodegenerative diseases, including Alzheimer’s disease. -
Aβ1–42 Aggregation Inhibitor
Aβ1–42 aggregation inhibitor 2 is a potent inhibitor of Aβ1-42 aggregation, which is significant in the study of Alzheimer's disease. This compound demonstrates strong antioxidant properties, effectively chelates metal ions, and alleviates oxidative stress. Additionally, it exhibits neuroprotective and anti-neuroinflammatory activities, making it a valuable tool for research focused on neurodegenerative disorders and potential therapeutic interventions. -
Amyloid-β Fragment
β-Amyloid (17-40) is a fragment of the Amyloid-β peptide that primarily targets neurotoxic pathways associated with Alzheimer's disease. This compound has demonstrated notable neurotoxic effects in SH-SY5Y and IMR-32 neuronal cell lines. Due to its biological activity, β-Amyloid (17-40) is a valuable tool for investigating the mechanisms underlying neurological diseases and for developing potential therapeutic strategies. -
BACE1 Inhibitor
CTS-21166 is a selective inhibitor of β-site amyloid precursor protein cleaving enzyme 1 (BACE1), designed to penetrate the blood-brain barrier effectively. It demonstrates the ability to reduce levels of amyloid-beta (Aβ) in the brain, making it a valuable tool for studying the pathogenesis of Alzheimer's disease. CTS-21166 is suitable for use in both in vitro and in vivo research applications focused on Alzheimer's and related neurodegenerative disorders. -
Aβ Fragment
(Gly22)-Amyloid β-Protein (1-42) is a peptide fragment of the amyloid β-protein (Aβ) with a specific mutation at Glu22 to Gly22. This modification enhances the aggregation tendency of Aβ, a key component in the formation of amyloid plaques associated with Alzheimer's disease. Research applications include studying the molecular mechanisms of amyloid aggregation and evaluating potential therapeutic strategies for Alzheimer's disease. -
Amyloid-β
β-Amyloid (10-35), amide targets amyloid-β, a key player in the pathogenesis of Alzheimer’s disease. Comprising 26 amino acids derived from the 10-35 region of the Aβ peptide, this reagent is critical for studying the aggregation and deposition of amyloid plaques. It is valuable for research applications focused on neurodegeneration, protein misfolding, and Alzheimer's pathology. -
Amyloid-β Inhibitor
YIAD-0205 is an orally bioavailable inhibitor of amyloid-β (Aβ) aggregation, specifically targeting Aβ(1-42). This compound exhibits significant in vivo efficacy in a transgenic mouse model of Alzheimer's disease carrying five familial mutations (5XFAD). Its application lies in Alzheimer's research, particularly in studies exploring therapeutic strategies aimed at mitigating Aβ-related neurodegeneration. -
Aβ Fragment
Amyloid β-Protein (5-42) is an Aβ fragment that plays a critical role in the formation of amyloid plaques, a pathological hallmark of Alzheimer's disease. This peptide exhibits neurotoxic properties and serves as a key research tool in studies investigating the mechanisms underlying amyloid aggregation and neurodegeneration. It is commonly utilized to evaluate potential therapeutic agents aimed at mitigating Alzheimer's disease-related cognitive decline. -
Amyloid β Inhibitor
Aβ-IN-3 is a potent inhibitor of amyloid β (Aβ) aggregation, specifically targeting Aβ42. This compound effectively inhibits the aggregation of Aβ42, making it a valuable tool in the study of amyloid-related pathologies. However, Aβ-IN-3 does not mitigate the neurotoxicity associated with Aβ42 in SH-SY5Y cells, nor does it alter the aggregation state of Aβ42 into a non-toxic form. Its primary applications lie in research focused on Alzheimer's disease and amyloid aggregation mechanisms. -
Nicardipine Metabolite
Dehydro nicardipine, a metabolite of Nicardipine, belongs to the dihydropyridine class of compounds. This compound selectively inhibits the aggregation of amyloid-beta (Aβ) monomers and regulates the extension and binding of soluble Aβ aggregates. Additionally, it alters the morphology of Aβ aggregates and inhibits their growth in length. Dehydro nicardipine is valuable for research applications focused on Alzheimer's disease. -
Aβ Inhibitor
PPI-1019 is an amyloid beta (Aβ) inhibitor that specifically targets the aggregation of Aβ peptides. This compound demonstrates potential neuroprotective effects, making it a valuable tool for researching neurodegenerative disorders, particularly Alzheimer's disease. Its role in modulating Aβ-related toxicity makes PPI-1019 significant for studies aimed at understanding the pathophysiology of amyloid plaque formation and developing therapeutic strategies. -
Amyloid-β
β-Amyloid (1-9) is an N-terminal fragment of the amyloid-β peptide that encompasses amino acid residues 1 to 9. This fragment contains a B cell epitope, making it valuable for immunological studies. Although it lacks T cell epitopes, β-Amyloid (1-9) remains capable of forming amyloid fibrils and does not diminish fibril polymorphism when removed from the full-length Alzheimer's amyloid-β peptide (1-40). This specificity makes it useful for research into Alzheimer’s disease and related neurodegenerative conditions. -
Amyloid β-Protein Mutat
(Lys22)-Amyloid β-Protein (1-42) is a modified variant of the wild-type Amyloid β-Protein (1-42) peptide, featuring a lysine substitution at position 22. This mutation enhances the peptide's propensity to interact with molecular targets involved in Alzheimer’s disease pathology. It is essential for studies investigating amyloid aggregation, neurotoxicity, and the design of potential therapeutic agents for neurological disorders. -
Aβ Oligomers Formation Inhibitor
Aβ-IN-6 is an Aβ oligomers formation inhibitor that effectively reduces pro-inflammatory cytokine release from microglia. This compound significantly promotes Nrf2 nuclear translocation, thereby interfering with the aggregation of Aβ oligomers. Aβ-IN-6 offers neuroprotective effects through modulation of redox-sensitive signaling pathways in in vivo oxidative stress models. Its oral bioactivity and combined anti-inflammatory, antioxidant, and anti-oligomeric properties make Aβ-IN-6 a valuable reagent for research into Alzheimer's disease. -
β-Amyloid (1-42) Dutch Mutation
(Gln22)-Amyloid β-Protein (1-42) is a variant of β-Amyloid (1-42) featuring the Dutch mutation (E22Q). This modified peptide demonstrates increased fibrillogenic and pathogenic characteristics, making it essential for studying amyloidogenesis and its implications in neurodegenerative diseases. Research applications include investigations into Alzheimer's disease mechanisms and the assessment of potential therapeutic interventions targeting amyloid aggregation. -
QPCTL Inhibitor
QP5020 is a selective QPCTL inhibitor with an IC50 value of 15 nM. This compound demonstrates notable antitumor efficacy, making it a valuable tool for cancer research. Its mechanism of action provides insights into the role of QPCTL in tumor biology and offers potential avenues for therapeutic exploration. -
Antiamyloid Agent
Squoxin is an antiamyloid agent that specifically targets Aβ1-42, effectively inhibiting its aggregation and fibril formation. This compound is capable of crossing the blood-brain barrier, making it relevant for neurological research. Additionally, Squoxin exhibits anthelmintic activity and possesses anti-inflammatory properties, which further supports its potential applications in various biological and therapeutic studies. -
APP Degrader
Aβ42-IN-4 is an APP degrader that effectively reduces the production of amyloid-β peptide Aβ42 by promoting the degradation of the amyloid precursor protein. This compound is valuable for research applications focused on neurodegenerative diseases, particularly Alzheimer's disease, where the accumulation of Aβ42 is a key pathogenic factor. Its ability to modulate APP levels makes Aβ42-IN-4 a relevant tool for investigating potential therapeutic strategies aimed at reducing amyloid plaque formation. -
Aβ42 Inhibitor
Doliroside A is an Aβ42-binding agent that exhibits an IC50 of 26.57 μM for Aβ42. By binding to Aβ42 nuclei and oligomers, it forms stable complexes that suppress Aβ42 fibrillation, redirecting it into off-pathway, amorphous oligomers. This compound serves as a valuable tool in Alzheimer's disease research, aiding in the understanding of Aβ42 aggregation mechanisms and potential therapeutic strategies. -
BACE1/2 Inhibitor
BACE1/2-IN-1 is a potent dual inhibitor of BACE1 and BACE2, exhibiting IC50 values of 0.01 μM and 0.0053 μM, respectively. This compound demonstrates a favorable pharmacokinetic profile characterized by a lower P-glycoprotein efflux ratio and enhanced passive permeability. In addition, BACE1/2-IN-1 is associated with increased metabolic stability in liver microsomes, making it a valuable tool for researching therapeutic strategies targeting amyloid precursor protein processing in Alzheimer's disease. -
Fusion Protein
Zamubafusp alfa is an immunoglobulin-peptide fusion protein that targets amyloid fibrils and highly sulfated heparan sulfate glycans. This compound enhances macrophage phagocytosis, facilitating the clearance of amyloid deposits. It is particularly relevant for research applications focused on systemic amyloidosis and the development of therapeutic strategies aimed at mitigating amyloid-related diseases. -
BACE1 Inhibitor
2,2′,4,4′-Tetrahydroxychalcone is a selective and potent inhibitor of Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) with an IC50 of 0.62 μM. This compound, derived from Isoliquiritigenin found in Glycyrrhiza uralensis, effectively inhibits the β-cleavage of amyloid precursor protein (APP), leading to a reduction in β-amyloid (Aβ) peptide production. 2,2′,4,4′-Tetrahydroxychalcone is used in research related to Alzheimer's disease, providing insights into potential therapeutic avenues for neurodegenerative conditions. -
Amylin Antagonist
AC 253 is an amylin antagonist that specifically inhibits the binding of 125I-adrenomedullin, demonstrating an IC50 value of 25 nM. This compound is valuable for research applications focused on metabolic disorders and neurodegenerative diseases, where modulation of amylin pathways may play a critical role. -
Aβ Fragment
Amyloid β-Protein (4-42) is a peptide fragment of the amyloid β-protein that is implicated in the pathogenesis of Alzheimer's disease. This Aβ fragment plays a critical role in the aggregation process that forms amyloid plaques, influencing neurotoxicity and synaptic dysfunction. It is commonly used in research focused on neurodegenerative diseases, enabling studies on amyloid aggregation, cell signaling pathways, and potential therapeutic approaches for Alzheimer's disease. -
BACE1 Inhibitor
AZ3971 is a selective BACE1 inhibitor that effectively penetrates the blood-brain barrier, while leaving γ-secretase activity unaffected. By reducing the production of amyloid-beta (Aβ), AZ3971 serves as a valuable tool in the study of Alzheimer's disease and related neurodegenerative disorders. Its oral bioavailability makes it particularly suitable for in vivo research applications. -
Aβ oligomerization Inhibitor
Aβ aggregation-IN-4 is an Aβ oligomerization inhibitor that targets and mitigates the neurotoxicity associated with amyloid-β protein (Aβ). By significantly reducing the formation of oligomeric complexes of Aβ (Aβ-OCs) without affecting total Aβ levels, it effectively attenuates Aβ oligomerization. This compound provides a valuable tool for researching the pathophysiology of Alzheimer's disease (AD) and exploring potential therapeutic strategies. Additionally, Aβ aggregation-IN-4 protects primary cortical neurons from oligomer-induced cell death, highlighting its relevance in neuroprotective studies. -
Tau/Amyloid-β Aggregation Inhibitor
TRV-1387 is a benzofurazan compound that functions as an inhibitor of tau and amyloid-β aggregation. It demonstrates significant biological activity in preventing the formation of toxic aggregates associated with neurodegenerative diseases, making it a valuable tool for research in Alzheimer's disease and related pathologies. TRV-1387 can be utilized to study the mechanisms of amyloid-related toxicity and to explore potential therapeutic strategies targeting protein aggregation. -
Tau/Aβ Inhibitor
D-687 is a selective inhibitor of Tau and amyloid-beta (Aβ) aggregation. It has demonstrated the ability to reverse Aβ1–42-induced neurotoxicity in SH-SY5Y neuronal cells, highlighting its significant neuroprotective effects. This compound is valuable for research focused on Alzheimer's disease and related neurodegenerative disorders. -
QC Inhibitor
Glutaminyl Cyclase Inhibitor 5 is a potent and selective inhibitor of human glutaminyl cyclase (hQC), exhibiting an IC50 value of 3.2 nM. This compound serves as a valuable tool for investigating the role of hQC in neurodegenerative diseases and related biological processes. It is applicable in various research studies focused on glutamate signaling and its implications in disease mechanisms. -
Amyloid-β Precursor
β-Amyloid Protein Precursor 770 (135-155) is a peptide derived from the amyloid precursor protein isoform APP 770, which plays a crucial role in the generation of amyloid-β peptides Aβ40 and Aβ42. This peptide serves as an important tool for studying the mechanisms of amyloidogenic processing and its implications in neurodegenerative diseases such as Alzheimer’s disease. Researchers can utilize this reagent in assays that investigate protein interactions, amyloid formation, and related signaling pathways. -
Tau/Aβ Inhibitor
D-688 is a potent inhibitor of Tau and amyloid-beta (Aβ), demonstrating significant neuroprotective properties. This compound effectively reverses Aβ1–42-induced toxicity in SH-SY5Y neuronal cells, making it a valuable tool for studying neurodegenerative processes. Additionally, D-688 improves the survival rate of Drosophila melanogaster models expressing the human tau protein isoform (2N4R), underscoring its potential in Alzheimer's disease research and related disorders. -
Amyloid-β
LPYFD-NH2 is a pentapeptide that targets the aggregation of amyloid-β (Aβ(1-42)). It demonstrates inhibitory activity against Aβ aggregation, making it a valuable tool for investigating the pathogenic mechanisms underlying Alzheimer’s disease. This compound is suitable for research applications focused on understanding amyloid-related processes in neurodegeneration. -
Anti-Amyloid-β Antibody
Merinetug is a humanized IgG1κ antibody specifically targeting amyloid beta (Aβ). This antibody plays a crucial role in disrupting the aggregation of Aβ, making it valuable for research into Alzheimer’s disease and related neurodegenerative conditions. Merinetug is utilized in various experimental applications, including therapies aimed at modulating amyloid pathology and understanding the mechanisms underlying amyloid-related neurotoxicity. -
Lipid Droplet Formation Inhibitor
Beauveriolide III is a specific inhibitor of lipid droplet formation, effectively reducing lipid accumulation in mouse macrophages. This compound plays a significant role in studies focused on lipid metabolism and its implications in metabolic disorders. Its utility in research can aid in understanding the biological pathways regulating lipid storage and inflammation in macrophage-associated pathologies. -
Amyloid β-Protein (1-40) Fluorescence
5-TAMRA-Amyloid β-Protein (1-40) is a fluorescently labeled peptide targeting the Amyloid β-Protein (1-40) with an excitation/emission wavelength of 544/572 nm. This reagent is designed for the study of amyloid aggregation, facilitating the investigation of Alzheimer's disease pathology. Its fluorescence properties make it suitable for applications in live-cell imaging and fluorescence microscopy, enabling researchers to track amyloid formation and accumulation in various biological contexts. -
AD Molecular Probe
Aftobetin is a non-invasive molecular probe targeting aggregated β-amyloid peptides (Aβ) for the early diagnosis of Alzheimer's disease (AD). This reagent can specifically bind to Aβ aggregates present in the lens of the eye, facilitating rapid and painless detection of AD in patients. Aftobetin serves as a valuable tool in both clinical diagnostics and research applications focused on neurodegenerative disease mechanisms. -
Amyloid-β
SCH 900229 is a selective γ-secretase inhibitor targeting presenilin 1 (PS1) with an Aβ40 IC50 value of 1.3 nM, demonstrating strong efficacy in reducing amyloid-β levels. This compound exhibits significant Aβ-lowering effects following oral administration in preclinical animal models. It has progressed to human clinical trials as a potential therapeutic agent for Alzheimer's disease, highlighting its relevance in neurodegenerative research. -
RAGE/SERT Inhibitor
RAGE/SERT-IN-1 is a potent inhibitor of receptor for advanced glycation end products (RAGE) and serotonin transporter (SERT), demonstrating IC50 values of 8.26 μM and 31.09 nM, respectively. This compound exhibits significant neuroprotective properties against Aβ25-35-induced neuronal damage and has been shown to alleviate depressive behaviors in murine models. RAGE/SERT-IN-1 is a valuable tool for studying the interplay between Alzheimer's disease and depression comorbidity. -
Aβ Aggregation Inhibitor
SEN 304 is an Aβ aggregation inhibitor that directly binds to Aβ(1-42), effectively delaying β-sheet formation while promoting the aggregation of toxic oligomers into a nontoxic form. This compound is primarily utilized in research focused on Alzheimer’s disease, providing insights into the mechanisms of neurodegeneration and potential therapeutic strategies. The ability of SEN 304 to modulate Aβ aggregation makes it a valuable tool for studying amyloid pathology. -
Anti-aggregation Compound
2,3-Dehydrosilybin A is an anti-aggregation compound that targets protein misfolding. This compound exhibits significant potential in preventing amyloid formation and related neurodegenerative disorders. Research applications include studying its impact on cellular longevity and its role in mitigating protein aggregation, making it valuable for exploring therapeutic approaches for age-related diseases. -
Amyloid-β Inhibitor
Aβ Fibrillization Modulator 1 targets amyloid-β (Aβ) by stabilizing Aβ monomers, thus inhibiting the formation of toxic fibrils associated with neurodegenerative diseases. This compound demonstrates potential in research applications focused on Alzheimer's disease and other amyloid-related disorders. By modulating fibrillization, it provides a valuable tool for investigating the mechanisms of amyloid aggregation and the development of therapeutic strategies. -
Aβ42 Inhibitor
2002-G12 is an Aβ42 inhibitor that effectively reduces Aβ42 toxicity by 76%. Its mechanism of action makes it a valuable tool for investigating Alzheimer's disease and studying the role of Aβ42 in neurodegenerative processes. Researchers can utilize 2002-G12 to explore potential therapeutic strategies targeting amyloid-beta aggregation and toxicity. -
Amyloid-β Inhibitor
KMS88009 is a potent amyloid-β oligomer inhibitor that directly disrupts the formation of these aggregates. This compound demonstrates significant potential in preserving cognitive function when administered preventively and reversing cognitive decline therapeutically. In studies using the APP/PS1 double transgenic mouse model, KMS88009 effectively reduced amyloid-β oligomer assembly and improved cognitive performance. Comprehensive evaluations of its physicochemical properties, pharmacokinetics, and toxicity further underscore KMS88009's promise as a therapeutic candidate for Alzheimer's disease. -
Amyloid-β
β-Amyloid (33-40) is a peptide derived from the beta-amyloid protein, encompassing amino acids 33 to 40. This peptide serves as a key target for studies investigating the aggregation processes related to neurodegenerative diseases, particularly Alzheimer’s disease. Its biological activity is critical for understanding amyloid pathology and exploring potential therapeutic strategies in Alzheimer’s research.
